Lon Cardon, who has served as chief scientific officer at BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) the past two years, has been promoted to a newly created position: chief scientific strategy officer. San Rafael, CA-based BioMarin says in the new role Cardon will be responsible for building the company’s drug pipeline. Before joining BioMarin, Cardon worked at GlaxoSmithKline (NYSE: [[ticker:GSK]]) as senior vice president of alternative discovery and development, and head of target sciences. BioMarin is preparing to file for FDA review of its experimental gene therapy for hemophilia.
